Generex' Oral-lyn: comparable to Lilly's Humulin

Toronto, Canada-headquartered drugmaker Generex Biotechnology, a specialist in buccal drug delivery, says that strong clinical results were presented at the 41st annual meeting of the European Association for the Study of Diabetes held in Athens, Greece, on September 14, from a 12-day comparison of Eli Lilly's injectable drug Humulin versus Oral-lyn, its proprietary oral insulin spray flagship product. The study found that both treatments induced similar glucodynamic responses.